H. pylori and gastric sleeve surgery are closely linked concerns in bariatric medicine, as an untreated Helicobacter pylori infection can increase the risk of complications following sleeve gastrectomy. During this procedure, approximately 75–80% of the stomach is removed, leaving a narrower gastric remnant that may be more vulnerable to ulceration and mucosal injury. UK bariatric centres widely recommend pre-operative screening and eradication of H. pylori to optimise surgical outcomes. This article explains why testing matters, what NHS and BOMSS guidance advises, how eradication is managed, and what follow-up care looks like after surgery.

What Is H. pylori and Why It Matters Before Bariatric Surgery

H. pylori colonises the gastric mucosa and is a recognised cause of peptic ulcer disease and gastric cancer; its presence before sleeve gastrectomy raises the risk of ulceration in the reduced gastric remnant.

Helicobacter pylori (H. pylori) is a gram-negative bacterium that colonises the gastric mucosa. UK prevalence is estimated at approximately 30–40% in adults, though rates vary considerably by age, ethnicity, and socioeconomic background, and are lower in younger cohorts. H. pylori is a well-established cause of chronic gastritis and peptic ulcer disease, and is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC/WHO) due to its association with gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. It is important to note that, whilst this classification reflects a genuine causal link, the absolute risk of gastric cancer for any individual with H. pylori infection remains low.

In the context of bariatric surgery — and gastric sleeve (sleeve gastrectomy) in particular — the presence of H. pylori carries clinical implications. During a sleeve gastrectomy, approximately 75–80% of the stomach is surgically removed, leaving a narrow tubular remnant. This anatomical change alters mucosal integrity and may increase susceptibility to ulceration in the gastric remnant.

Key reasons why H. pylori is considered clinically relevant before gastric sleeve surgery include:

• Increased ulcer risk: The reduced gastric remnant may be more vulnerable to ulceration post-operatively, and H. pylori is a recognised contributing factor.

• Potential impact on mucosal healing: Active infection may affect healing at the staple line, though the evidence specifically linking H. pylori to staple-line complications in sleeve gastrectomy remains limited and mixed.

• Diagnostic considerations post-surgery: Whilst upper GI endoscopy (OGD) is generally feasible after sleeve gastrectomy, altered anatomy can affect the interpretation of some tests. Endoscopic access is more substantially affected after Roux-en-Y gastric bypass.

For these reasons, identifying and treating H. pylori before surgery is widely regarded as an important step in optimising patient safety. Patients should discuss their infection status with their bariatric team well in advance of any planned procedure.

NHS Guidelines on H. pylori Testing Prior to Gastric Sleeve

No single NHS England directive mandates universal pre-operative screening, but BOMSS supports testing and most UK bariatric centres include urea breath test or stool antigen test in their standard pre-operative workup.

In the United Kingdom, guidance on pre-operative H. pylori screening for bariatric surgery is informed by NICE guidance on dyspepsia and H. pylori management (NICE CG184 and NICE CKS: Dyspepsia — Helicobacter pylori), the British Society of Gastroenterology (BSG), and the British Obesity and Metabolic Surgery Society (BOMSS). There is no single national NHS England directive mandating universal pre-operative H. pylori screening; however, many UK bariatric centres include it as part of their standard pre-operative workup, and BOMSS supports this approach. Patients should confirm the specific protocol at their treating centre.

Where pre-operative H. pylori testing is undertaken, validated methods include:

• Urea breath test (UBT): A reliable non-invasive test with high sensitivity and specificity; widely used in UK practice.

• Stool antigen test: An equally validated first-line alternative, particularly where UBT is unavailable; both are recommended in NICE CKS guidance.

• Upper GI endoscopy with biopsy: Indicated where there are additional upper GI symptoms, alarm features, or as part of centre-specific pre-operative assessment protocols, allowing direct visualisation of the gastric mucosa alongside histological testing.

To avoid false-negative results, patients should observe the following washout periods before testing:

• Antibiotics: stop at least four weeks before testing

• Proton pump inhibitors (PPIs): stop at least two weeks before testing

• Bismuth-containing preparations: stop at least two weeks before testing

• H2-receptor antagonists: stop at least 24 hours before testing

Serology (blood antibody testing) is not recommended for diagnosing active H. pylori infection in UK practice, as it cannot reliably distinguish between current and past infection.

Patients referred through NHS bariatric pathways should expect H. pylori screening to be discussed as part of their pre-operative assessment. Those pursuing surgery through private providers should confirm whether this screening is included in their pre-surgical protocol and should raise the question directly with their surgical team if uncertain.

Treatment and Eradication of H. pylori Before Surgery

First-line UK treatment is a seven-day triple therapy regimen of a PPI, amoxicillin, and clarithromycin; eradication must be confirmed by breath or stool test before surgery proceeds.

When H. pylori is detected prior to gastric sleeve surgery, eradication treatment should be initiated promptly to allow sufficient time for confirmation of clearance before the procedure. In line with NICE CKS, NICE CG184, and BSG guidance, first-line eradication therapy in the UK typically consists of a seven-day triple therapy regimen:

• A proton pump inhibitor (PPI) (e.g., omeprazole 20 mg twice daily)

• Amoxicillin 1 g twice daily

• Clarithromycin 500 mg twice daily

However, clarithromycin-containing regimens should be avoided in patients with prior macrolide antibiotic exposure or where local clarithromycin resistance rates are known to be high. In such cases, bismuth quadruple therapy may be preferred as first-line treatment; clinicians should follow local antimicrobial guidance and BSG recommendations.

In patients with a documented penicillin allergy, metronidazole is substituted for amoxicillin. Adherence to the full course is essential, as incomplete treatment significantly increases the risk of antibiotic resistance and treatment failure.

If first-line therapy fails, second-line bismuth quadruple therapy — typically incorporating bismuth, a PPI, tetracycline, and metronidazole — is recommended, usually for 10–14 days in line with UK guidance. Tetracycline is contraindicated in pregnancy; patients who are pregnant or planning pregnancy should inform their prescriber before starting any eradication regimen.

Patients taking statins or anticoagulants such as warfarin should be aware that clarithromycin can interact with these medicines; the prescribing clinician or pharmacist should review concurrent medications before starting treatment.

Following completion of eradication therapy, most UK bariatric centres recommend confirming successful eradication before proceeding to surgery. Patients should follow their own centre's protocol. A urea breath test or stool antigen test should be performed no sooner than four weeks after completing antibiotics and at least two weeks after stopping PPIs, to avoid false-negative results.

Patients should be aware that:

• Side effects of eradication therapy can include nausea, diarrhoea, a metallic taste, and mild abdominal discomfort.

• Alcohol should be avoided during metronidazole-containing regimens.

• Surgery should generally be deferred until eradication is confirmed, in line with the bariatric centre's protocol.

• Suspected side effects from eradication therapy should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app).

Open communication between the patient, their GP, and the bariatric surgical team is essential to ensure treatment is completed and verified within the pre-operative timeline.

Post-Operative Risks If H. pylori Is Left Untreated

Untreated H. pylori may increase the risk of gastric remnant ulceration, gastrointestinal haemorrhage, and chronic gastritis after sleeve gastrectomy; red-flag symptoms require immediate emergency assessment.

Proceeding with gastric sleeve surgery in the presence of an untreated H. pylori infection may increase the risk of certain post-operative complications, though the evidence specifically linking H. pylori to serious complications after sleeve gastrectomy — as distinct from other bariatric procedures such as Roux-en-Y gastric bypass — remains limited and mixed. Patients and clinicians should be aware of the following potential concerns:

• Gastric remnant or staple-line ulceration: H. pylori is a recognised risk factor for peptic ulceration, and the gastric remnant following sleeve gastrectomy may be susceptible. The term 'marginal ulceration' is more specifically associated with anastomotic ulcers in gastric bypass; after sleeve gastrectomy, ulceration typically occurs at or near the staple line or within the remnant.

• Gastrointestinal haemorrhage: Active infection may increase mucosal fragility; however, robust evidence directly attributing post-sleeve bleeding to H. pylori is limited.

• Chronic gastritis: Persistent inflammation of the gastric remnant may contribute to ongoing dyspeptic symptoms and nutritional compromise.

• Long-term cancer risk: H. pylori is a recognised carcinogen; whilst long-term data specific to post-sleeve patients are still emerging, eradication before surgery is prudent.

It is worth noting that upper GI endoscopy (OGD) is generally technically feasible after sleeve gastrectomy, allowing diagnostic access to the gastric remnant when clinically indicated. Endoscopic access is more substantially limited after Roux-en-Y gastric bypass.

Prevention through pre-operative screening and eradication remains preferable to managing complications after surgery. Patients experiencing persistent upper abdominal pain, nausea, or symptoms suggestive of gastrointestinal bleeding following sleeve gastrectomy should seek prompt medical review.

Red-flag symptoms requiring urgent assessment (call 999 or go to A&E):

• Vomiting blood or material resembling coffee grounds (haematemesis)

• Black, tarry, or bloody stools (melaena or rectal bleeding)

• Severe or worsening abdominal pain, particularly with fever

• Dizziness, collapse, or loss of consciousness

Any new or worsening upper abdominal symptoms that are not immediately life-threatening should be reported promptly to your GP or bariatric team.

Follow-Up Care and Monitoring After Gastric Sleeve Surgery

Post-operative care includes PPI therapy for at least three to six months, regular blood tests at 3, 6, and 12 months, micronutrient supplementation, and prompt reporting of any upper GI symptoms.

Comprehensive follow-up care following gastric sleeve surgery is essential for monitoring both nutritional status and gastrointestinal health. For patients who had confirmed H. pylori infection pre-operatively, post-operative monitoring should include verification that eradication was successful and surveillance for any signs of recurrence or mucosal complications.

In the immediate post-operative period, patients are typically maintained on a PPI to protect the gastric remnant and reduce acid-related injury to the staple line. The duration of PPI therapy varies by centre, but many UK bariatric units recommend continuation for at least three to six months post-surgery. Patients should not discontinue PPIs without guidance from their surgical or medical team.

Ongoing follow-up should be guided by BOMSS recommendations and local bariatric centre protocols, and typically includes:

• Regular dietetic review: To monitor nutritional intake, identify deficiencies, and support dietary adaptation to the reduced gastric capacity.

• Blood tests: Routine haematological and biochemical monitoring is recommended at intervals specified by the bariatric team — commonly at 3, 6, and 12 months post-operatively, then annually. Core tests for sleeve gastrectomy patients typically include full blood count (FBC), ferritin, vitamin B12, folate, urea and electrolytes (U&Es), liver function tests (LFTs), calcium, vitamin D, and parathyroid hormone (PTH), in line with BOMSS guidance.

• Micronutrient supplementation: Patients are usually advised to take a bariatric-specific multivitamin and mineral supplement, along with additional vitamin D, calcium, iron, and vitamin B12 as indicated by blood results and local protocol. Patients should follow their bariatric team's specific supplementation recommendations.

• Symptom monitoring: Patients should report any new or worsening upper abdominal pain, reflux, vomiting, or signs of gastrointestinal bleeding to their GP or bariatric team promptly.

• Repeat H. pylori testing: If symptoms suggestive of recurrence or new ulceration develop, non-invasive testing (urea breath test or stool antigen test) or upper GI endoscopy may be indicated.

When to seek urgent help: Contact 999 or go to A&E immediately for haematemesis, melaena, severe abdominal pain with fever, or collapse. For persistent or worsening symptoms that are not immediately life-threatening, contact your GP or bariatric team without delay rather than waiting for a routine appointment.

Patients are encouraged to remain engaged with their bariatric follow-up programme, as early identification of complications — including those related to H. pylori — significantly improves outcomes. Any concerns about symptoms or medication should be discussed with a GP or the specialist bariatric team.

Frequently Asked Questions